Insmed Q3 Rally Masks $40M Insider Sales at Highs
Insmed rallied on strong Q3 results, but the COO and CMO had already liquidated $40M at prices ($127-$133) the stock now trades well below ($105.07). The gap raises questions about management confiden
Insmed Q3 Sparks Rally as Insiders Sold $39M at Highs
NEW YORK, November 3 —
Insmed Incorporated (INSM) posted a Q3 2026 earnings rally, but the company's COO and CMO had already sold nearly $40 million in shares at prices above $127 that the stock has since failed to reclaim. That gap between insider exit and today's $105.07 close is the question the revenue story cannot answer alone.
- Trailing revenue of $1.52 billion grew 268.4% year-over-year at an 84.4% gross margin.
- COO Roger Adsett liquidated $31.96M in shares at $133.27 in August 2026; the CMO sold $3.49M at $127, $129.
- Shares trade at $105.07 against an analyst consensus target of $194.18; Q3 EPS missed estimates by 24.2%.
ARIKAYCE Is Real; Brensocatib Is the Multiple
Insmed's commercial engine is ARIKAYCE, an inhaled therapy for refractory NTM lung infections approved in the United States, Europe, and Japan. That franchise, with its 84.4% gross margin, reflects a narrow specialty-pharma dynamic: an underserved indication, premium pricing, limited alternatives. The company disclosed Q3 results in an 8-K filed October 29. Brensocatib, an oral DPP1 inhibitor in Phase 3 for bronchiectasis and marketed in Japan as Brinsupri, is the drug a 180x forward P/E requires. With trailing operating cash flow at negative $596 million, that multiple is entirely a bet on Phase 3, a scenario worth stress-testing with a DCF calculator.
The Selling Pattern
COO Roger Adsett liquidated 239,850 shares at $133.27 in August 2026 for $31.96 million; the CMO sold $3.49 million at $127 to $129. The stock now trades at $105.07, below every open-market insider sale price in that window. These were the executives most directly responsible for ARIKAYCE's commercial execution and brensocatib's clinical trajectory. The EPS record compounds the picture: across four reported quarters, results have ranged from a 31.7% miss to a 90.8% beat before last quarter's 24.2% shortfall, an erratic pattern that makes the insider timing harder to attribute purely to scheduled diversification.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| INSM | $23.1B | 141.4x | -40.2% |
| CYTK | $8.7B | n/a | +4.0% |
| ALNY | $21.5B | 14.4x | -62.7% |
| NTRA | $56.2B | n/a | +92.9% |
| RARE | $1.7B | 74.4x | -49.8% |
| PTCT | $5.7B | 27.9x | -10.1% |
One Checkpoint, Two Outcomes
The forward checkpoint is brensocatib's Phase 3 bronchiectasis readout. With $1.15 billion in cash against $0.73 billion in debt, Insmed has the runway to reach it. Short interest at 6.9% of float against institutional ownership reported at 105.1% indicates a shareholder base concentrated almost entirely in long-only hands, a structure where adverse trial news would find thin natural buying. Analyst consensus sits at $194.18, implying the market prices in success; Q4 2026 EPS will show whether last quarter's miss was an outlier. Run the free Insmed Incorporated deep-dive → for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Insmed beat Q3 earnings estimates?
No. Insmed's Q3 EPS missed analyst estimates by 24.2%. The miss fits an erratic pattern: across four reported quarters, results have ranged from a 31.7% miss to a 90.8% beat.
Why did Insmed executives sell $40M in stock?
The article does not state their stated reasons. COO Roger Adsett liquidated $31.96M at $133.27 in August 2026, while the CMO sold $3.49M at $127-$129, prices well above the stock's current $105.07. Both executives directly oversee ARIKAYCE's commercial execution and brensocatib's clinical progress.
What is Insmed's core business?
ARIKAYCE, an inhaled therapy for refractory NTM lung infections approved in the US, Europe, and Japan. With an 84.4% gross margin, it reflects specialty pharma: an underserved indication, premium pricing, and limited alternatives.
What's the forward catalyst for Insmed stock?
Brensocatib's Phase 3 bronchiectasis readout. The stock's 180x forward P/E assumes success, and the company has $1.15 billion in cash against $0.73 billion in debt to reach it. Institutional ownership at 105.1% means adverse trial news would encounter concentrated long-only holders.
Insmed Incorporated's Q3 2026 earnings release sent shares higher despite another EPS miss, reigniting a split between bulls citing explosive revenue growth and bears noting that the company's most senior operators sold nearly $40 million in stock near what now appear to be recent price highs. The rally lands amid a CFO departure, two rounds of analyst price-target cuts, and a commercial launch in Japan — a lot of signal for investors to untangle.